Divi's Laboratories Share PriceDivi's Laboratories

-57.65 (-1.65%)
  • Advice
  • Hold
As on 09 June, 2023 | 13:33 BSE: 532488 NSE: DIVISLAB

Divi's Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Divi's Laboratories

Start SIP

Divi's Laboratories Share Price

  • Over 1 Month 5.42%
  • Over 3 Month 22.22%
  • Over 6 Month 5.38%
  • Over 1 Year -0.88%

Divi's Laboratories Key Statistics

P/E Ratio 50.1
PEG Ratio -1.3
Market Cap Cr 91,376
Price to Book Ratio 7.2
EPS 68.1
Dividend 0.9
Relative Strength Index 60.09
Money Flow Index 86.73
MACD Signal 80.28
Average True Range 85.39

Divi's Laboratories Investment Rating

  • Master Rating:
  • Divis Laboratories (Nse) has an operating revenue of Rs. 7,767.51 Cr. on a trailing 12-month basis. An annual revenue de-growth of -11% needs improvement, Pre-tax margin of 30% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 5% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 60 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Divi's Laboratories Financials
IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 1,9081,6901,8232,2042,495
Operating Expenses Qtr Cr 1,4191,2801,2141,3661,399
Operating Profit Qtr Cr 4894096098381,096
Depreciation Qtr Cr 8787858381
Interest Qtr Cr 00000
Tax Qtr Cr 149128116152183
Net Profit Qtr Cr 319311487692883

Divi's Laboratories Technicals


Current Price
-57.65 (-1.65%)
  • Bullish Moving Average
  • ___
  • 11
  • Bearish Moving Average
  • ___
  • 5
  • 20 Day
  • ₹3418.1
  • 50 Day
  • ₹3283.36
  • 100 Day
  • ₹3237.93
  • 200 Day
  • ₹3354.22
  • 20 Day
  • ₹3391.64
  • 50 Day
  • ₹3234.28
  • 100 Day
  • ₹3113.91
  • 200 Day
  • ₹3312.82

Divi's Laboratories Resistance and Support

First Resistance ₹3539.85
Second Resistance ₹3580
Third Resistance ₹3605.4
RSI 60.09
MFI 86.73
MACD Single Line 80.28
MACD 82.98
First Resistance ₹3474.3
Second Resistance ₹3448.9
Third Resistance ₹3408.75

Divi's Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 451,831 18,294,637 40.49
Week 501,715 21,648,994 43.15
1 Month 708,780 23,524,407 33.19
6 Month 572,828 19,716,733 34.42

Divi's Laboratories Result Highlights

Divi's Laboratories Synopsis

NSE-Medical-Generic Drugs

Divi's Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 7625.30 Cr. and Equity Capital is Rs. 53.09 Cr. for the Year ended 31/03/2023. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.
Market Cap 91,957
Sales 7,625
Shares in Float 12.74
No of funds 751
Yield 0.85
Book Value 7.31
U/D Vol ratio 1.4
LTDebt / Equity
Beta 0.31

Divi's Laboratories

Owner NameMar-23Dec-22Sep-22Jun-22
Promoters 51.94%51.94%51.94%51.94%
Mutual Funds 13.15%12.68%13.62%13.85%
Insurance Companies 6.78%6.76%5.81%
Foreign Portfolio Investors 14.67%15.15%15.4%16.52%
Financial Institutions/ Banks 0.11%0.12%0.11%0.09%
Individual Investors 9.61%9.52%9.2%9.53%
Others 3.74%3.83%3.92%8.07%

Divi's Laboratories Management

Name Designation
Dr. Ramesh B V Nimmagadda Non Exe.Chairman&Ind.Director
Dr. Murali K Divi Managing Director
Dr. Kiran S Divi WholeTime Director & CEO
Ms. Nilima Prasad Divi Whole Time Director
Mr. Madhusudana Rao Divi Whole Time Director
Mr. N V Ramana Executive Director
Mr. K V K Seshavataram Independent Director
Dr. G Suresh Kumar Independent Director
Mr. R Ranga Rao Independent Director
Prof. Sunaina Singh Independent Director
Dr. S Ganapaty Independent Director
Mr. K V Chowdary Independent Director

Divi's Laboratories Forecast

Price Estimates


Other Analyst Rating

Divi's Laboratories Corporate Action

Date Purpose Remarks
2023-05-20 Audited Results & Final Dividend
2023-02-03 Quarterly Results
2022-11-07 Quarterly Results
2022-08-12 Quarterly Results
2022-05-23 Audited Results & Dividend
Date Purpose Remarks
2022-08-12 FINAL Rs.30.00 per share(1500%)Dividend

Divi's Laboratories MF Shareholding

Name Amount(cr)
SBI Nifty 50 ETF 149735
SBI Equity Hybrid Fund Regular Payout Inc Dist cum Cap Wdrl 56300
ICICI Prudential Balanced Advantage Fund Growth 45584
UTI Nifty 50 Exchange Traded Fund 38624
SBI Bluechip Fund Regular Growth 35770

About Company

Established in 1990, the Indian multinational pharmaceuticals company Divis Laboratories Limited is a manufacturer of active pharmaceutical ingredients (APIs)including generic APIs, Nutraceutical Ingredients, and Custom Synthesis of the APIs providing high-quality products to over 95 countries. It is headquartered in Hyderabad, Telangana, India.

Divis Laboratories is among the world's leading manufacturers of generic APIs, offering a competitive advantage over the entire life cycle of the products. Competent in handling high-potency, high-energy reactions to fulfil the unmet needs of the big pharma customers, Divis Laboratories is the second most valuable pharmaceutical firm in India by market value.


In 1990, Divis Laboratories was founded as Divis Research Centre. Initially, the company began developing commercial techniques for the production of APIs and intermediates. In 1994, Divis Research Centre rebranded as Divis Laboratories Limited to indicate its entry into the API and intermediates manufacturing industry.

1997: The United Kingdom's SGS–Yarsley certifies Divis Laboratories as ISO–9002 compliant.
1999: The European Directorate issues a Certificate of Suitability (CoS) for the Naproxen manufactured by Divis Laboratories.
2001: London's BVQI grants Divis OHSAS–18001 Certification (for its Occupational Health and Safety Management Systems).
2003: Divis inaugurates a new research centre dubbed "DRC–Vizag".
2003: Went for IPO and was listed on the BSE, NSE, and HSE stock markets.
2007: Set up Nutraceuticals facility at Unit 2
2008: The third US-FDA examination of Choutuppal(Unit-1).
2008: The Visakhapatnam(Unit–2) is inspected by the KFDA.
2010: Letter of approval received by Divis Laboratories for the establishment and development of a new pharmaceutical ingredient manufacturing unit in SEZ at Visakhapatnam.
2016: First Anvisa (Brazil) inspection
2020: 8th USFDA inspection at unit 2.

Shareholding Pattern

Up until March 2022, the Promoters of Divis Laboratories held 51.94% of the business's shares, FII/FPI held around 18.45%, and mutual funds increased their holdings to 13.68 %, and institutional investors held 36.77% of the company. In addition, public holdings account for 11.3% of the company's equity. The company's equity is held by retail and other investors to the tune of 4.6%.

Corporate Social Responsibility

Corporate Social Responsibility at Divis Laboratories consists of social programs, community service, and environmental impact awareness. Some key initiatives are mentioned below.

Child Empowerment Initiatives- 

Promoting Education
Preventive Healthcare
Empowering Women
Safe Drinking water
Swaach Bharat

Healthcare Initiatives-

Free Eye and Dental care Camps
ORT training and pulse polio campaigns
Incentives for Family Planning and awareness campaigns on HIV/ Aids, epidemics and malaria

Initiatives for Development of Village-

Laying of CC Roads in Villages
Construction of underground Drainages in Villages
Construction of Overhead Tanks
Laying of Gravel Roads from villages to Agricultural Fields
Facilitate Street lights in Villages


Top Line

Over the last 5 years, the audited financial statements were INR 3928 crores in 2018, INR 5036.24 crore in 2019, INR 5500 crore in 2020, INR 6861 crore in 2021, and INR 8991 crore in 2022.

Bottom Line

The profit recorded has grown exponentially from INR 1219 crore to INR 3676 crore in 5 yrs. The highest growth can be shown in the years 2021-2022 which is around INR 1000 crores. This is due to a substantial rise in revenue and a decrease in selling, general, and administrative costs.

Net Worth

The net worth of Divis Laboratory as calculated till 2022 is INR 11691.35 crore. It has grown by a whopping INR 5668.59 crore over the last 5 yrs.


Divi's Laboratories FAQs

What is Share Price of Divi's Laboratories ?

Divi's Laboratories share price is ₹3442 As on 09 June, 2023 | 13:19

What is the Market Cap of Divi's Laboratories ?

The Market Cap of Divi's Laboratories is ₹91375.6 Cr As on 09 June, 2023 | 13:19

What is the P/E ratio of Divi's Laboratories ?

The P/E ratio of Divi's Laboratories is 50.1 As on 09 June, 2023 | 13:19

What is the PB ratio of Divi's Laboratories ?

The PB ratio of Divi's Laboratories is 7.2 As on 09 June, 2023 | 13:19

What does Divis Laboratories do?

Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.

Is Divis Laboratories good for the long term?

Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.

Is Divis Laboratories debt-free?

Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

Who is the owner of Divis Laboratories?

Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).

How to buy Divis Laboratory?

You can easily buy Divis Laboratory shares by registering at 5Paisa and by setting up a Demat account in your name.


Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number